A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)
Conditions: Chronic Kidney Disease (CKD); Secondary Hyperparathyroidism (SHPT) Intervention: Drug: Paricalcitol Sponsor: AbbVie Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Chronic Kidney Disease | Hyperparathyroidism | Pediatrics | Research | Study | Urology & Nephrology